These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 32982179)

  • 21. Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 × 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases.
    Oymanns M; Daum-Marzian M; Assaf C
    Curr Oncol; 2024 Sep; 31(9):5412-5421. PubMed ID: 39330028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma.
    Watson S; Marx JB
    J Adv Pract Oncol; 2019; 10(8):883-888. PubMed ID: 33425472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 24. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
    Mukai M; Maeda H; Narushima K; Mould DR; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments.
    Stuver R; Geller S
    Front Immunol; 2023; 14():1284045. PubMed ID: 37868986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
    Khodadoust MS; Rook AH; Porcu P; Foss F; Moskowitz AJ; Shustov A; Shanbhag S; Sokol L; Fling SP; Ramchurren N; Pierce R; Davis A; Shine R; Li S; Fong S; Kim J; Yang Y; Blumenschein WM; Yearley JH; Das B; Patidar R; Datta V; Cantu E; McCutcheon JN; Karlovich C; Williams PM; Subrahmanyam PB; Maecker HT; Horwitz SM; Sharon E; Kohrt HE; Cheever MA; Kim YH
    J Clin Oncol; 2020 Jan; 38(1):20-28. PubMed ID: 31532724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series.
    Teoli M; Mandel VD; Franceschini C; Saraceni PL; Cicini MP; Ardigò M
    Eur Rev Med Pharmacol Sci; 2022 Nov; 26(21):8118-8128. PubMed ID: 36394762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
    Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.
    Ohuchi K; Fujimura T; Kambayashi Y; Amagai R; Lyu C; Tanita K; Sato Y; Aiba S
    Dermatol Ther; 2020 Jul; 33(4):e13487. PubMed ID: 32362053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
    Xu S; Foss F
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):1017-1028. PubMed ID: 33554707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
    Van-de-Velde V; Zhou Y
    J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
    Nguyen CN; Iyer SP; Duvic M; Barde PJ; Nair A; Routhu KV; Huen AO
    Invest New Drugs; 2023 Apr; 41(2):350-355. PubMed ID: 37004644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series.
    Amagai R; Kambayashi Y; Ohuchi K; Furudate S; Hashimoto A; Asano Y; Fujimura T
    Dermatol Ther; 2022 Nov; 35(11):e15858. PubMed ID: 36161437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
    Fernández-Guarino M; Ortiz P; Gallardo F; Llamas-Velasco M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mogamulizumab-associated rash - Case series and review of the literature.
    Hansen I; Abeck F; Menz A; Schneider SW; Booken N
    J Dtsch Dermatol Ges; 2024 Aug; 22(8):1079-1086. PubMed ID: 38924340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome.
    Molloy K; Vico C; Ortiz-Romero PL; Scarisbrick JJ
    Br J Dermatol; 2021 May; 184(5):978-981. PubMed ID: 33314065
    [No Abstract]   [Full Text] [Related]  

  • 39. Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study.
    Mitsunaga K; Bagot M; Ram-Wolff C; Guenova E; von Gugelberg C; Hodak E; Amitay-Laish I; Papadavid E; Jonak C; Porkert S; Scarisbrick J; Applewaite R; Beylot-Barry M; Nicolay J; Quaglino P; Sanches JA; Cury-Martins J; Lora-Pablos D; Ortiz P
    Br J Dermatol; 2024 Aug; 191(3):419-427. PubMed ID: 38596857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.
    Hawkins N; Muszbek N; Evans R; Dequen-O'Byrne P; Jones T; McNamara L
    J Comp Eff Res; 2022 Aug; 11(11):805-813. PubMed ID: 35678206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.